Plain-English translation of NCT06447376 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a medication that blocks inflammatory proteins in your body, can prevent or reduce a serious side effect called cytokine release syndrome (CRS) when given alongside , a newer type of cancer-fighting treatment. is a special antibody that helps your immune system recognize and kill lymphoma cells. The study is exploring whether giving before the main treatment can make the experience safer and more tolerable.
can trigger a severe inflammatory reaction in the body as it activates the immune system to fight cancer cells. This medication aims to prevent or reduce that reaction, making the treatment safer for patients who are at higher risk for this complication.
You likely qualify if…
You likely don't qualify if…
You would receive as an infusion one hour before starting injections. The cancer treatment itself is given in 28-day cycles over several months, with the option to continue for up to 24 cycles or stop earlier if your cancer goes into complete remission. Starting in the second cycle, you may also receive additional chemotherapy medications. Throughout the study, you'll have regular visits to monitor your response, side effects, and blood work.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States